Management of chronic hepatitis C virus infection in patients with end-stage renal disease: A review

Therapeutics and Clinical Risk Management

Volumn 11, Issue , 2015, Pages 329-338

  Valadez, Jonathan Aguirre ^a   Juárez, Ignacio García ^a   Pedrero, Rodolfo Rincón ^a   Torre, Aldo ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Chronic kidney disease; Hemodialysis; Hepatitis C virus; Interferon

Indexed keywords

ALPHA INTERFERON; ASUNAPREVIR; CYCLOSPORIN; ERYTHROPOIETIN; FALDAPREVIR; INTERFERON; PARITAPREVIR; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS; THYMOCYTE ANTIBODY; VANIPREVIR;

ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; DISEASE COURSE; DISEASE TRANSMISSION; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELASTOGRAPHY; EPIDEMIC; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEMODIALYSIS; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE COMPLEX NEPHRITIS; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION CONTROL; KIDNEY DONOR; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER CIRRHOSIS; LIVER INJURY; LOW DRUG DOSE; MONOTHERAPY; MORBIDITY; MORTALITY; NEUROLOGIC DISEASE; PERITONEAL DIALYSIS; PREVALENCE; PROGNOSIS; RISK FACTOR; SEROPREVALENCE; SURVIVAL RATE; TREATMENT DURATION; VIRUS LOAD;

EID: 84924745794     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S74282     Document Type: Article

References (85)

1. Finelli L, Miller J, Tokars J, Arduimo M. National surveillance of dialysis-associated diseases in the United States. Semin Dial. 2005;18:52-61.
2. Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004;65:2335-2342.
3. Jadoul M, Poignet JL, Geddes C, et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant. 2004;19:904-909.
4. Wreghitt T. Blood-borne virus infections in dialysis units - a review. Rev Med Virol. 1999;9:101-109.
5. Amiri Z, Shakib A, Toorchi M. Seroprevalence of hepatitis C and risk factors in haemodialysis patients in Guilan, Islamic Republic of Iran. East Mediterr Health J. 2005;11:372-376.
6. Sypsa V, Psichogiou M, Katsoulidou A, et al. Incidence and patterns of hepatitis C virus seroconversion in a cohort of hemodialysis patients. Am J Kidney Dis. 2005;45:334-343.
7. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, et al. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol. 2007;18:1584-1593.
8. Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol. 2000;11:1896-1902.
9. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther. 2004;20:1271-1277.
10. Legendre C, Garrigue V, Le Bihan C, et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation. 1998;65:667-670.
11. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29:257-263.
12. Fabrizi F, Poordad F, Martin P. Hepatitis C infection and the patient with end stage renal disease. Hepatology. 2002;36:3-10.
13. Martin P, Fabrizi F. Hepatitis C virus and kidney disease. J Hepatol. 2008;49:613-624.
14. Fabrizi F, Lampertico P, Lunghi G, Mangano S, Aucella F, Martin P. Review article: hepatitis C virus infection and type-2 diabetes mellitus in renal diseases and transplantation. Aliment Pharmacol Ther. 2005;21:623-632.
15. Sezer S, Ozdemir F, Akcay A, Arat Z, Boyacioglu S, Haberal M. Renal transplantation offers a better survival in HCV-infected ESRD patients. Clin Transplant. 2004;18:619-623.
16. Al-Freah M, Zeino Z, Heneghan M. Management of hepatitis C in patients with chronic kidney disease. Curr Gastroenterol Rep. 2012;14:78-86.
17. Patel P, Thompson N, Kallen A, Arduino M. Epidemiology, surveillance, and prevention of hepatitis C virus infections in hemodialysis patients. Am J Kidney Dis. 2010;56:371-378.
18. Tokars J, Frank M, Alter M, Arduino M. National surveillance of dialysis-associated diseases in the United States, 2000. Semin Dial. 2002;15:162-171.
19. Gohar S, Khalil R, Elaish N, Khedr E, Ahmed M. Prevalence of antibodies to hepatitis C virus in hemodialysis patients and renal transplant recipients. J Egypt Public Health Assoc. 1995;70:465-484.
20. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2008;Suppl 109:S1-S99.
21. [No authors listed]. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001;50:1-43.
22. Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment and efficacy and harms. Am J Kidney Dis. 2008;51:263-277.
23. Liu CH, Liang CC, Huang KW, et al. Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients. Clin J Am Soc Nephrol. 2011;6:1057-1065.
24. Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat. 2007;14:697-703.
25. Okuda K, Yokosuka O. Natural history of chronic hepatitis C in patients on hemodialysis: case control study with 4-23 years of follow up. World J Gastroenterol. 2004;10:2209-2212.
26. Trevizoli JE, de Paula Menezes R, Ribeiro Velasco LF, et al. Hepatitis C is less aggressive in hemodialysis patients than in nonuremic patients. Clin J Am Soc Nephrol. 2008;3:1385-1390.
27. Furusyo N, Hayashi J, Ariyama I, et al. Maintenance hemodialysis decreases serum hepatitis C virus (HCV) RNA levels in hemodialysis patients with chronic HCV infection. Am J Gastroenterol. 2009;95:490-496.
28. Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat. 2012;19:601-607.
29. Azevedo HA, Villela-Nogueira CA, Perez RM, et al. Similar HCV viral load levels and genotype distribution among end-stage renal disease patients on hemodialysis and HCV infected with normal renal function. J Nephrol. 2007;20:609-616.
30. Fabrizi F, Messa P, Martin P. Impact of hemodialysis therapy on hepatitis C virus infection: a deeper insight. Int J Artif Organs. 2009;32:1-11.
31. Rostaing L, Peres C, Tkaczuk J, et al. Ex vivo flow cytometry determination of intracytoplasmic expression of IL-2, IL-6, IFN-gamma and TNFalpha in monocytes and T-lymphocytes in chronic hemodialysis patients. Am J Nephrol. 2000;20:18-26.
32. Wang SM, Liu H, Chou C, Huang C, Shih C, Chen W. Mortality in hepatitis C-positive patients treated with peritoneal dialysis. Perit Dial Int. 2008;28:183-187.
33. Bloom RD, Lake JR. Emerging issues in hepatitis C virus positive liver and kidney transplant recipients. Am J Transplant. 2006;6:2232-2237.
34. Morales JM, Aguado JM. Hepatitis C and renal transplantation. Curr Opin Organ Transplant. 2012;17:609-615.
35. Roth D, Reddy KR, Kupin W. Long-term impact of HCV on clinical outcomes and liver histology in kidney recipients. Am J Transplant. 2004;A478:289.
36. Paramesh AS, Davis JY, Mallikarjun C, et al. Kidney transplantation alone in ESRD patients with hepatitis C cirrhosis. Transplantation. 2012;94:250-254.
37. Campos S, Parsikia A, Zaki RF, Ortiz JA. Kidney transplantation alone in ESRD patients with hepatitis C cirrhosis. Transplantation. 2012;94:65-66.
38. Justa S, Mintz R, Mintz M, et al. Serial measurements of hepatitis C viral load by real-time polymerase chain reaction among recipients of living-donor renal transplants: a short-term follow-up study from a single center. Transplant Proc. 2010;42:3568-3573.
39. Roth D, Gaynor J, Reddy K, et al. Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol. 2011;22:1152-1160.
40. Alric L, Di-Martino V, Selves J, et al. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology. 2002;123:1494-1499.
41. Manuel O, Baid-Agrawal S, Moradpour D, Pascual M. Immunosuppression in hepatitis C virus-infected patients after kidney transplantation. Contrib Nephrol. 2012;76:97-107.
42. Toth C, Pascual M, Chung R, et al. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy. Transplantation. 1998;66:1254-1258.
43. Siddiqui AR, Abbas Z, Luck NH, et al. Experience of fibrosing cholestatic hepatitis with hepatitis C virus in kidney transplant recipients. Transplant Proc. 2012;44:721-724.
44. Cimsit B, Assis D, Caldwell C, et al. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation. Transplant Proc. 2011;43:905-908.
45. Stokes M. Immune complex glomerulonephritis in patients with hepatitis C. Saudi J Kidney Dis Transpl. 2000;11:396-404.
46. Vallet-Pichard A, Fontaine H, Mallet V, Pol S. Viral hepatitis in solid organ transplantation other than liver. J Hepatol. 2011;55:474-482.
47. Ingsathit A. Kamanamool N, Thakkinstian A, Sumethkul V. Survival advantage of kidney transplantation over dialysis in patients with hepatitis C: a systematic review and meta analysis. Transplantation. 2013;95:943-948.
48. Espinosa M, Martin-Malo A, Alvarez de Lara MA, et al. Risk of death and liver cirrhosis in anti-HCV-positive long term hemodialysis patients. Nephrol Dial Transplant. 2001;16:1669-1674.
49. Solez K, Colvin RB, Racusen LC, et al. Banff'05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant. 2007;7:518-526.
50. Fabrizi F, Dixit V, Messa P, Martin P. Interferon monotherapy of chronic hepatitis C in patients: meta-analysis of clinical trials. J Viral Hepat. 2008;15:79-88.
51. Chan T, Wu P, Lau J, Lok A, Lai C, Cheng I. Interferon treatment for hepatitis C virus infection in patients on haemodialysis. Nephrol Dial Transplant. 1997;12:1414-1419.
52. Liu C, Liang C, Lin J. Pegylated interferon alpha 2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut. 2008;57:525-530.
53. Gordon C, Uhlig K, Lau J, Schmid C, Levey A, Wong J. Interferon for hepatitis C virus in hemodialysis - an individual patient meta-analysis of factors associated with sustained virological response. Clin J Am Soc Nephrol. 2009;4:1449-1458.
54. Covic A, Maftei I, Mardare N, et al. Analysis of safety and efficacy of PEGylated interferon alpha 2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. J Nephrol. 2006;19:794-801.
55. Wang KL, Xing HQ, Zhao H, et al. Efficacy and tolerability of low dose interferon-α in hemodialysis patients with chronic hepatitis C virus infection. World J Gastroenterol. 2014;20:4071-4075.
56. Fabrizi F, Dixit V, Messa P, Martin P. Interferon monotherapy of chronic hepatitis C in patients: meta-analysis of clinical trials. J Viral Hepat. 2008;15:79-88.
57. Liu C, Liang C, Lin J. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment naive dialysis patients with chronic hepatitis C: a randomised study. Gut. 2008;57:525-530.
58. Bruchfeld A, Stahle L, Andersson J, Schvarez R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection - a pilot study. J Viral Hepat. 2001;8:287-292.
59. Tan A, Brouwer J, Glue P. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant. 2001;16:193-195.
60. Mousa D, Abdalla A, Al-Shoail G, Al-Sulaiman M, Al-Hawas F, Al-Khader A. Alpha interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc. 2004;36:1831-1834.
61. Fabrizi F, Dixit V, Martin P, Messa P. Combined antiviral therapy of hepatitis C virus in dialysis patients: meta analysis of clinical trials. J Viral Hepat. 2011;18:e253-e269.
62. Rendina M, Schena A, Castellaneta N. The treatment of chronic hepatitis C with peginterferon alfa 2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol. 2007;46:768-774.
63. Djordjević V, Kostić S, Stefanović V. Treatment of chronic hepatitis C with interferon alpha in patients on maintenance hemodialysis. Nephron. 1998;79:229-231.
64. Liu C, Liang C, Liu C. Pegylated interferon alfa 2 plus low dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy. Gut. 2009;58:314-316.
65. Hassan Q, Roche B, Buffet C, et al. Liver-kidney recipient with chronic viral hepatitis C treated with interferon-alpha. Transpl Int. 2012;25:941-947.
66. Al-Harbi A, Malik G, Subaity Y, Mansy H, Abutaleb N. Treatment of acute hepatitis C virus infection with alpha interferon in patients with hemodialysis. Saudi J Kidney Dis Transpl. 2005;16:293-297.
67. Fabrizi F, Dixit V, Messa P, Martin P. Interferon therapy of acute hepatitis C in dialysis patients: meta-analysis. J Viral Hepat. 2012;19:784-791.
68. Kamar N, Toupance O, Buchler M, Sandres-Saune K, Izopet J, Durand D. Evidence that clearance of hepatitis C virus RNA after interferon therapy in dialysis patients in sustained after renal transplantation. J Am Soc Nephrol. 2003;12:2092-2098.
69. Roth D, Bloom R. Selection and management of hepatitis C-virus infected patients for the kidney transplant waiting list. Contrib Nephrol. 2012;176:66-76.
70. Hassan Q, Roche B, Buffet C, Sessade T, Samuel D, Charpentier B, Durrbach A. Liver-kidney recipient with chronic viral hepatitis C treated with interferon-alpha. Transpl Int. 2012;25:941-947.
71. Wei F, Liu F, Hu H, Ren H, Hu P. Interferon based antiviral therapy for hepatitis C virus infection after renal transplantation: an update meta-analysis. PLoS One. 2014;9:1-11.
72. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. The effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 2011;54:20-27.
73. Woodside KJ, Idshihara K, Theisen JE, et al. Use of kidneys from hepatitis C seropositive donors shortens waitlist time but does not alter one-yr outcome. Clin Transplant. 2003;17:433-437.
74. Kucirka LM, Singer AL, Ros RA, et al. Underutilization of hepatitis C-positive kidneys for hepatitis C positive recipients. Am J Transplant. 2010;10:1238-1246.
75. Kucirka LM, Peters TG, Segev DL. Impact of donor hepatitis C virus infection status on death and need for liver transplant in hepatitis C virus-positive kidney transplant recipients. Am J Kidney Dis. 2012;60:112-120.
76. Morales JM, Campistol JM, Domínguez-Gil B, et al. Long term experience with kidney transplantation from hepatitis C-positive donors into hepatitis C-positive recipients. Am J Transplant. 2010;10:2453-2462.
77. Morales JM, Campistol JM, Castellano G, et al. Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV. Kidney Int. 1995;47:236-240.
78. Veroux P, Veroux M, Sparacino V, et al. Kidney transplantation from donors with viral B and C hepatitis. Transplant Proc. 2006;38:996-998.
79. Natov SN, Lau JY, Ruthazer R, Schmid CH, Levey AS, Pereira BJ. Hepatitis C virus genotype does not affect patient survival among renal transplant candidates. The New England Organ Bank Hepatitis C Study Group. Kidney Int. 1999;56:700-706.
80. Treitel M, Marbury T, Preston RA, et al. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. Clin Pharmacokinet. 2012;51:619-628.
81. Durmortier J, Guillaud O, Gagnieu MC, et al Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible? J Clin Virol. 2013;56:146-149.
82. US Food and Drug Administration. Sovaldi prescribing information. 2013. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000ClinPharmR.pdf. Accessed July 16, 2014.
83. Sovaldi (sofosvubir) [package insert]. Foster City, CA, USA: Gilead Sciences, Inc; 2013.
84. Ghany M, Nelson D, Strader D, Thomas D, Seeff L. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433-1444.
85. Gordon CE, Balk EM, Becker BN, et al. KDOQI US Commentary on the KDIGO clinical practice guideline for the prevention diagnosis, evaluation, and treatment of hepatitis C in CKD. Am J Kidney Dis. 2008;52:815-825.